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Background. Enteric fever, caused by Salmonella Typhi and Salmonella Paratyphi A, is the leading cause of bacterial febrile 
disease in South Asia.
Methods. Individual data from 2092 patients with enteric fever randomized into 4 trials in Kathmandu, Nepal, were pooled. 
All trials compared gatifloxacin with 1 of the following comparator drugs: cefixime, chloramphenicol, ofloxacin, or ceftriaxone. 
Treatment outcomes were evaluated according to antimicrobial if S. Typhi/Paratyphi were isolated from blood. We additionally 
investigated the impact of changing bacterial antimicrobial susceptibility on outcome.
Results. Overall, 855 (41%) patients had either S. Typhi (n = 581, 28%) or S. Paratyphi A (n = 274, 13%) cultured from blood. 
There were 139 (6.6%) treatment failures with 1 death. Except for the last trial with ceftriaxone, the fluoroquinolone gatifloxacin was 
associated with equivalent or better fever clearance times and lower treatment failure rates in comparison to all other antimicrobials. 
However, we additionally found that the minimum inhibitory concentrations (MICs) against fluoroquinolones have risen signifi-
cantly since 2005 and were associated with increasing fever clearance times. Notably, all organisms were susceptible to ceftriaxone 
throughout the study period (2005–2014), and the MICs against azithromycin declined, confirming the utility of these alternative 
drugs for enteric fever treatment.
Conclusion. The World Health Organization and local government health ministries in South Asia still recommend fluoro-
quinolones for enteric  fever. This policy should change based on the evidence provided here. Rapid diagnostics are urgently required 
given the large numbers of suspected enteric fever patients with a negative culture.
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Enteric (typhoid) fever is a systemic infection caused by the 
Salmonella enterica serovars Typhi and Paratyphi A, B, and 
C. Enteric fever is a significant cause of morbidity and mortality 
in low-income regions [1] and was responsible for an estimated 
12.2 million disability-adjusted life-years and >190 000 deaths 
globally in 2010 [2]. The fatality rate of enteric fever is low (<1%) 
but is higher when antimicrobial therapy is delayed or unavail-
able [3]. Therefore, antimicrobials are essential for the clinical 
management of enteric fever. Chloramphenicol, ampicillin, and 
cotrimoxazole were first-line treatments for enteric fever until 
the early 1990s when the increasing incidence of multidrug-re-
sistant (MDR; defined as resistance to these 3 antimicrobial 
drugs) S. Typhi organisms led to the use of fluoroquinolones 
[4, 5]. Yet, organisms with reduced susceptibility against fluoro-
quinolones became a problem in Asia soon after their introduc-
tion [6, 7]. Recent phylogeographic analyses that document an 
ongoing epidemic of a global antimicrobial resistance (AMR) 
S. Typhi lineage suggest that the potential for regional or global 
dispersal of a lineage exhibits resistance to fluoroquinolones is 
now a real threat [8–10]. In the absence of effective and accessi-
ble vaccines and lack of sanitation improvements, development 
of tailored antimicrobial therapy recommendations is critical to 
reduce morbidity and prevent disease transmission.
In Kathmandu, Nepal, S. Typhi and S. Paratyphi A  are the 
most commonly isolated organisms from the blood of febrile 
adults and children [11, 12]. Over the last decade we conducted 
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4 randomized, controlled trials (RCTs) to evaluate enteric fever 
treatment in this endemic region [13–16]. Our aim in this 
study was to use the largest collection of individual patient data 
assembled to date from enteric fever treatment trials to evaluate 
the effect of treatment drug on differences in clinical outcome 
between S. Typhi and S. Paratyphi A infections and those with 
blood culture-negative enteric fever. We further sought to com-
pare the antimicrobial susceptibility profiles over time between 
S. Typhi and S. Paratyphi A  isolates and to investigate their 
impact on outcome. An in-depth understanding of trends and 
clinical implications of AMR enteric fever should guide policy-
makers and clinicians in decisions regarding treatment in an era 
of rapidly diminishing therapeutic options.
METHODS
Ethical Approval
Written informed consent, which was required for participa-
tion in all trials, was provided by a parent or adult guardian if a 
patient was aged <18 years. The Nepal Health Research Council 
Ethics Committee and the Oxford Tropical Research Ethics 
Committee of the United Kingdom provided ethical approval 
for all 4 studies.
Patient Populations and Study Procedures
Individual patient data for this study were derived from 4 RCTs 
conducted at Patan Hospital in Kathmandu, Nepal, between 
2005 and 2014, the methods and results of which have been 
described previously [13–16]. Patients who presented to the 
outpatient or emergency department with fever lasting longer 
than 3 days with a clinical diagnosis of enteric fever (undiffer-
entiated fever >38°C with no focus of infection) were eligible. 
Patients were excluded if they were pregnant or lactating, were 
aged <2  years or weighed <10  kg, showed any signs of com-
plications (jaundice, shock, gastrointestinal bleeding), showed 
hypersensitivity to the relevant trial drugs, or had been treated 
with a study drug in the week prior to going to the hospital. 
The study procedures between the 4 trials were comparable; 
however, there were several minor protocol differences between 
studies (outlined in Supplementary Table 1).
Patients were randomly assigned to 1 of 2 arms in each trial. 
Each trial was composed of a gatifloxacin arm (10 mg/kg/day, 
single dose orally for 7 days) and a comparator arm, which was 
cefixime (20 mg/kg/day, 2 doses orally for 7 days) [13], chlo-
ramphenicol (75 mg/kg/day, 4 divided oral doses for 14 days) 
[14], ofloxacin (20 mg/kg/day, 2 divided oral doses for 7 days) 
[15], or ceftriaxone (intravenous; 60 mg/kg for patients aged 
2–13 years or 2 g for patients aged ≥14 years) [16]. Gatifloxacin 
was the constant comparator because it is inexpensive and given 
once daily.
Fever clearance time (FCT) was defined as the time from 
the first dose of a study drug until the temperature dropped 
to ≤37.5°C and remained below this temperature for at least 
2 days. The composite endpoint treatment failure summarized 
unfavorable outcomes and was defined as the occurrence of 
at least 1 of the following: persistent fever (FCT of more than 
7 days [trials 1 and 4] or more than 10 days [trials 2 and 3] after 
treatment initiation), the need for rescue treatment, microbi-
ological failure (blood culture positive for Salmonella) on day 
8, relapse or disease-related complications within 31  days of 
treatment initiation, or death. Blood was taken from all patients 
for microbiological culture on enrollment and on day 8 for cul-
ture-positive individuals or those with a potential relapse.
Microbiological investigations have been described previously 
[13–16]. Blood samples from adult patients were inoculated into 
media containing tryptone soya broth and sodium polyanethol 
sulfonate. For children, BacTEC Ped Plus/F bottles were used. 
Positive bottles were cultured onto MacConkey agar and pre-
sumptive Salmonella colonies were identified using biochemical 
tests and serotype-specific antisera. During all 4 trials, minimum 
inhibitory concentrations (MICs) were determined against the 
following antimicrobials unless otherwise noted: Augmentin, 
ampicillin, amoxicillin, azithromycin (2006–2011), cefixime 
(2005), chloramphenicol, ciprofloxacin (2006–2014), ceftri-
axone, gatifloxacin, nalidixic acid, ofloxacin (2006–2014), and 
cotrimoxazole (2006–2009, 2011–2014), and against tetracy-
cline by E-test (AB Biodisk, Sweden).
Statistical Analyses
Data from the trials were combined and analyzed using Stata 
(v 13.1; College Station, Texas). Plots were drawn in R v3.1.1 
(R Foundation, Vienna, Austria) using the ggplot2 package. 
Demographics and clinical variables were tabulated and com-
pared between serovars. Comparisons of clinical parame-
ters between patient populations were structured as logistic 
regressions with the patient population (either culture posi-
tive/negative or S. Typhi/S. Paratyphi A) as the main covariate 
and adjustment for age stratum (binary: <16 years/≥16 years). 
Multivariable models with random effects were fitted to adjust 
for study heterogeneity as follows: FCT was evaluated using 
Kaplan-Meier estimates and Cox proportional hazard models 
with treatment group and age as covariates; logistic regression 
was used to determine the odds of treatment failure between 
treatment arms, controlling for age; and linear regression was 
used to evaluate the relationship between FCT and log2 MIC, 
also controlling for age. Generalized additive models (GAMs; 
identity link, cubic spline) were used to examine potential non-
linear trends of MIC over time.
RESULTS
Baseline Characteristics
Between 2005 and 2014 there were 2118 patients with clini-
cally suspected enteric fever randomized into 4 trials; data from 
2092 (99%) patients were evaluated (Figure  1). Of these, 855 
(41%) were culture positive for either S. Typhi (n = 581, 28%) or 
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S. Paratyphi A (n = 274, 13%). Throughout the study period there 
were 139 (6.6%) treatment failures including 1 death. The median 
patient age was 17 years (interquartile range [IQR], 10–23); 66% 
were male (Table 1). There was no significant difference in age 
between the culture-negative and culture-positive patients; 
however, S. Typhi patients were significantly younger (median, 
16  years; IQR, 9–21) than S. Paratyphi A  patients (median, 
19.5 years; IQR, 13–24) (P < .001) (Table 2). There was no dif-
ference in the sex distribution between culture-positive/cul-
ture-negative and S. Typhi/S. Paratyphi A populations (Table 2).
There were several significant differences in clinical history 
between patient populations after controlling for age (Table 2). 
Culture-negative patients were significantly more likely to 
report coughing (40%) and vomiting (22%) than culture-pos-
itive patients (31% and 17%, respectively). Culture-positive 
patients, however, reported diarrhea (24%) more often than 
culture-negative patients (17%) in addition to a higher tem-
perature (median, 39.0°C and 38.7°C, respectively). Among 
the culture-positive patients, those with an S. Typhi infection 
were significantly more likely to report a history of anorexia 
(78%), coughing (33%), and diarrhea (28%) compared to the 
S. Paratyphi A patients (71%, 25%, and 15%, respectively) and 
presented with higher temperatures (median, 39.0°C vs 38.8°C). 
Salmonella Paratyphi A patients were significantly more likely 
Figure 1. Enrollment of patients into enteric fever treatment trials in Nepal. Flow chart showing enrollment of patients into the 4 individual, randomized, controlled trials 
according to antimicrobial treatment and blood culture result.
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to report a history of previous typhoid illness (23%) compared 
to S. Typhi patients (12%). Additionally, there were several 
significant differences in hematology parameters between the 
culture-negative/culture-positive patients and the S. Typhi/S. 
Paratyphi A patients (Table 1), despite the majority of the values 
falling within normal ranges. Asparate aminotransaminase and 
alanine aminotransaminase were significantly elevated in the 
culture-positive patients (median, 51 U/L and median, 38 U/L, 
respectively) compared to culture-negative patients (median, 42 
U/L and median, 31 U/L, respectively).
Treatment Failure
The number of patients who failed treatment in each treat-
ment arm is shown in Table 3. Failure rates between antimi-
crobial treatment arms were largely similar when stratified by 
microbiological culture result, with a few notable exceptions. 
Compared to gatifloxacin, culture-positive patients were sig-
nificantly more likely to fail treatment when administered 
cefixime (odds ratio [OR], 10.7; 95% confidence interval 
[CI], 3.72–30.61; P  <  .001). Culture-negative patients were 
more likely to fail with cefixime (OR, 7.13; 95% CI, 2.82–18.0; 
P < .001), ceftriaxone (OR, 19.3; 95% CI, 8.02–46.5; P < .001), 
and chloramphenicol (OR, 3.67; 95% CI, 1.52–8.86; P = .004) 
compared to gatifloxacin.
Fever Clearance Times
The FCTs of the various patient populations are shown in 
Figure  2 and Table  4. Among the culture-positive patient 
population, S. Typhi patients treated with cefixime (hazard 
ratio [HR], 0.36; 95% CI, 0.25–0.54; P  <  .001) and ceftriax-
one (HR, 1.53; 95% CI,1.01–2.31; P  =  .043) had significantly 
longer FCTs than S. Typhi patients treated with gatifloxacin. 
In the culture-positive patients, those infected with S. Typhi 
also had significantly longer FCTs than S. Paratyphi A patients 
when treated with cefixime (HR, 2.18; 95% CI,1.25–3.80; 
P  =  .006; Table  4). However, S. Paratyphi A–infected patients 
had longer FCTs when treated with chloramphenicol compared 
to S. Typhi–infected patients (HR, 0.069; 95% CI, 0.49–0.97; 
P =  .031). Compared to gatifloxacin, culture-negative patients 
fared significantly worse when treated with cefixime (HR, 0.56; 
Table 1. Baseline Characteristics of Patients Enrolled in 4 Enteric Fever Treatment Trials
Characteristic
Trial 1 Trial 2 Trial 3 Trial 4 Total
N
n (11) or Median 
(IQR) N
n (11) or Median 
(IQR) N
n (11) or Median 
(IQR) N
n (11) or Median 
(IQR) N
n (11) or Median 
(IQR)
Age (11) 382 17 (9–23) 844 16 (9–22) 623 17 (9–23) 239 19 (15–23) 2088 17 (10–23)
Male sex 382 247 (64.7) 844 540 (64.0) 627 406 (64.8) 239 180 (75.3) 2092 1373 (65.6)
Weight (kg) 382 45 (24–53) 842 42 (21–52) 627 45 (25–54) 237 50 (40–56) 2088 45 (24–53)
Duration of illness before admission 
(days)
382 5 (3–6) 844 5 (4–7) 625 5 (4–7) 180 5 (4–7) 2031 5 (4–7)
Treatment with antimicrobials in the 
past 2 weeks
379 238 (62.8) 724 694 (95.9) 623 428 (68.7) 210 109 (51.9) 1936 1469 (75.9)
Previous history of typhoid 382 61 (16.0) 844 138 (16.4) 626 103 (16.5) 238 37 (15.5) 2090 339 (16.2)
Family history of typhoid 382 62 (16.2) 844 140 (16.6) 625 164 (26.2) 239 35 (14.6) 2090 401 (19.2)
Typhoid vaccination 382 2 (0.5) 844 0 (11) 625 0 (11) 238 11 (4.6) 2089 13 (0.6)
Temperature at admission (°C) 379 38.9 (38.3–39.5) 844 38.9 (38.2–39.4) 626 38.6 (38.2–39.0) 235 38.8 (38.3–39.4) 2084 38.8 (38.2–39.4)
Headache 382 370 (96.9) 844 749 (88.7) 627 541 (86.3) 239 211 (88.3) 2092 1871 (89.4)
Anorexia 382 289 (75.7) 844 632 (74.9) 627 455 (72.6) 239 173 (72.4) 2092 1549 (74.0)
Abdominal pain 382 32 (8.4) 844 33 (3.9) 626 25 (4.0) 235 62 (26.4) 2087 152 (7.3)
Cough 382 142 (37.2) 844 277 (32.8) 627 246 (39.2) 239 91 (38.1) 2092 756 (36.1)
Nausea 382 132 (34.6) 844 258 (30.6) 627 174 (27.8) 239 124 (51.9) 2092 688 (32.9)
Vomiting 382 57 (14.9) 844 172 (20.4) 627 118 (18.8) 239 69 (28.9) 2092 416 (19.9)
Diarrhea 382 86 (22.5) 844 161 (19.1) 627 105 (16.7) 239 59 (24.7) 2092 411 (19.6)
Constipation 382 41 (10.7) 844 105 (12.4) 627 79 (12.6) 239 31 (13.0) 2092 256 (12.2)
Hepatomegaly 382 19 (5.0) 844 113 (13.4) 626 7 (1.1) 231 0 (11) 2083 139 (6.7)
Splenomegaly 382 35 (9.2) 844 119 (14.1) 626 6 (1.0) 231 2 (0.9) 2083 162 (7.8)
Haematocrit (11) 370 40 (37–44) 831 39 (36–43) 624 38 (36–42) 235 39 (36–43) 2060 39 (36–43)
Leucocyte count (×109/L) 370 7.0 (5.5–9.0) 831 6.3 (5.0–8.1) 624 6.0 (4.8–7.7) 239 5.9 (4.7–7.3) 2064 6.3 (5.0–8.0)
Platelet count (×109/L) 356 190 (160–235) 800 190 (164–226) 615 174 (145–216) 239 168 (150–209) 2010 184 (153–220)
AST (U/L) 373 47 (36–62) 835 45 (34–61) 624 47 (34–67) 233 49 (36–70) 2065 46 (35–65)
ALT (U/L) 373 33 (24–48) 836 29 (20–43) 624 37 (28–53) 234 45 (31–63) 2067 34 (24–50)
Salmonella Typhi isolated 382 119 (31.2) 844 249 (29.5) 627 132 (21.1) 239 81 (33.9) 2092 581 (27.8)
S. Paratyphi A isolated 382 50 (13.1) 844 103 (12.2) 627 86 (13.7) 239 35 (14.6) 2092 274 (13.1)
No growth or culture negative 382 213 (55.8) 844 492 (58.3) 627 409 (65.2) 239 123 (51.5) 2092 1237 (59.1)
Trials: 1, gatifloxacin/cefixime [13]; 2, gatifloxacin/chloramphenicol [14]; 3, gatifloxacin/ofloxacin [15]; 4, gatifloxacin/ceftriaxone [16].
Abbreviations: ALT, alanine aminotransaminase; AST, asparate aminotransaminase; IQR, interquartile range.
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95% CI, 0.43–0.71; P < .001) and ceftriaxone (HR, 0.42, 95% CI, 
0.31–0.57; P < .001).
Antimicrobial Susceptibility Trends
As shown in Figure  3, the MICs for S. Paratyphi A  were sig-
nificantly higher than those for S. Typhi with all antimicrobi-
als (P  <  .001, Kruskal-Wallis), with the exception of cefixime 
(P  =  .375). Figure  4 shows the MIC time trends by serovar, 
which were significantly nonlinear over time for all antimicro-
bials in both serovars (GAM, P < .001 with the exception of S. 
Paratyphi A/ciprofloxacin [P =  .052] and S. Paratyphi A/nali-
dixic acid [P = .003]). Most notably, the MICs against the fluo-
roquinolones rose significantly over time, and the MICs against 
azithromycin declined between 2007 and 2010. Last, all isolates 
were susceptible to ceftriaxone throughout the study period.
Impact of Antimicrobial Resistance on Clinical Outcomes
Increasing MICs against fluoroquinolones led to longer FCTs 
in S. Typhi patients. As shown in Figure 5, an increasing (log2) 
MIC was associated with longer FCTs in patients treated with 
Table 2. Demographic and Clinical Characteristics of Culture-Negative, Culture-Positive, Salmonella Typhi, and S Paratyphi A Patients
Characteristic
Culture Negative Culture Positive
P Valuea
S. Typhi S. Paratyphi A
P ValueaN
n (11) or Median 
(IQR) N
n (11) or 
Median (IQR) N
n (11) or 
Median (IQR) N
n (11) or Median 
(IQR)
Age (11)b 1236 17 (9–24) 852 17 (10–22) .692 578 16 (9–21) 274 19.5 (13–24) <.001
Male sexb 1237 818 (66.1) 855 555 (64.9) .565 581 373 (64.2) 274 182 (66.4) .525
Weight (kg) 1234 44 (23–54) 854 46 (25–53) .854 580 43.5 (22–52) 274 49 (38–55) <.001
Duration of illness before admission (days) 1203 5 (4–7) 828 5 (4–7) .500 565 5 (4–7) 263 5 (4–6) .102
Treatment with antimicrobials in the past 
2 weeks
1146 861 (75.1) 790 608 (77.0) .330 532 414 (77.8) 258 194 (75.2) .440
Previous history of typhoid 1236 208 (16.8) 854 131 (15.3) .276 581 68 (11.7) 273 63 (23.1) <.001
Family history of typhoid 1236 242 (19.6) 854 159 (18.6) .657 580 107 (18.4) 274 52 (19.0) .400
Typhoid vaccination 1234 9 (0.7) 855 4 (0.5) .511 581 1 (0.2) 274 3 (1.1) .073
Temperature at admission (°C) 1233 38.7 (38.1–39.2) 851 39 (38.4–39.5) <.001 577 39 (38.5–39.5) 274 38.8 (38.2–39.2) <.001
Headache 1237 1098 (88.8) 855 773 (90.4) .348 581 518 (89.2) 274 255 (93.1) .237
Anorexia 1237 903 (73.0) 855 646 (75.6) .190 581 451 (77.6) 274 195 (71.2) .036
Abdominal pain 1237 479 (38.7) 855 258 (30.2) .067 581 261 (44.9) 274 97 (35.4) .061
Cough 1237 495 (40.0) 855 261 (30.5) <.001 581 193 (33.2) 274 68 (24.8) .011
Nausea 1237 394 (31.9) 855 294 (34.4) .310 581 198 (34.1) 274 96 (35.0) .853
Vomiting 1237 271 (21.9) 855 145 (17.0) .010 581 106 (18.2) 274 39 (14.2) .324
Diarrhea 1237 210 (17.0) 855 201 (23.5) <.001 581 161 (27.7) 274 40 (14.6) <.001
Constipation 1237 154 (12.4) 855 102 (11.9) .775 581 63 (10.8) 274 39 (14.2) .114
Hepatomegaly 1234 84 (6.8) 849 55 (6.5) .847 578 40 (6.9) 271 15 (5.5) .804
Splenomegaly 1234 85 (6.9) 849 77 (9.1) .069 578 48 (8.3) 271 29 (10.7) .224
Hematocrit (11) 1219 39 (36–43) 841 39 (36–43) .573 569 39 (35–43) 272 40 (37–44) .006
Leucocyte count (×109/L) 1220 6.4 (5.0–8.6) 844 6.1 (4.9–7.5) <.001 572 6.2 (4.9–7.5) 272 5.8 (4.8–7.2) .528
Platelet count (×109/L) 1187 187 (157–229) 823 180 (150–210) .002 555 180 (151–214) 268 180 (150–210) .469
AST (U/L) 1220 42 (32–59) 845 51 (40–69) <.001 573 54 (42–71) 272 47 (37.5–66) .023
ALT (U/L) 1220 31 (21–46.5) 847 38 (28–53) <.001 575 39 (28–53) 272 36 (28–49.5) .564
Abbreviations: IQR, interquartile range; AST, asparate aminotransaminase; ALT, alanine aminotransaminase.
aP values derived from logistic regression (categorical variables) or linear regression (continuous variables) with outcome characteristic of interest and a covariate of culture positivity or 
serovar, controlling for age (<15 years/≥16 years). 
bP values derived using Fisher exact test for categorical data and the Kruskal-Wallis test for continuous data (not controlled for age).
Table 3. Proportion of Enteric Fever Patients With Treatment Failure by Culture Result and Treatment
Treatment Arm
Culture Negative Culture Positive Salmonella Typhi Salmonella Paratyphi A
Total n (11) Total n (11) Total n (11) Total n (11)
Gatifloxacin 617 9 (1.5) 440 36 (8.2) 298 26 (8.7) 142 10 (7.0)
Cefixime 105 10 (9.5) 77 26 (33.8) 54 19 (35.2) 23 7 (30.4)
Ceftriaxone 65 15 (23.1) 54 4 (7.4) 38 3 (7.9) 16 1 (6.3)
Chloramphenicol 243 12 (4.9) 175 14 (8.0) 125 11 (8.8) 50 3 (6.0)
Ofloxacin 207 5 (2.4) 109 8 (7.3) 66 7 (10.6) 43 1 (2.3)
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gatifloxacin (number of hours increase in FCT for each 2-fold 
increase in MIC (β = 8.1; 95% CI, 5.3–10.8; P < .001) and ofloxa-
cin (β = 8.4; 95% CI, 2.2–14.5; P = .008). Longer FCTs were also 
observed with increasing MICs against ciprofloxacin in S. Typhi 
patients treated with ofloxacin or gatifloxacin (β = 6.88; 95% CI, 
4.9–8.9; P < .001). However, we found no significant association 
between FCT and (log2) MIC against the fluoroquinolones in 
the S. Paratyphi A patients (all P > .05). Additionally, there was 
no significant association between FCT and MIC for the other 
antimicrobials tested. Last, patients infected with an S. Typhi 
isolate that was nonsusceptible to ciprofloxacin (MIC ≥0.12 μg/
mL) were more likely to experience treatment failure (29/211, 
13.7%) when treated with ofloxacin or gatifloxacin compared 
to patients infected with S. Typhi organisms susceptible to cip-
rofloxacin (MIC < 0.12 μg/mL; 2/79, 2.5%; OR, 5.16; 95% CI, 
1.1–23.2; P  =  .033). Conversely, we did not identify a similar 
relationship in those infected with S. Paratyphi A (8/149 [5.4%] 
vs 1/6 [16.7%]; OR, 0.32; 95% CI, 0.03–3.15; P  =  .329), the 
majority of which exhibited reduced susceptibility against cip-
rofloxacin (MIC ≥0.12 μg/mL; 211/221, 96%).
DISCUSSION
Enteric fever remains the leading cause of febrile bacterial 
illness in Kathmandu [12]. With alarming AMR rates, a lack 
of immunization as a public health tool, and slow sanitation 
improvements, tailored antimicrobial therapies for the prevail-
ing AMR profiles are required. Using systematic, longitudinal, 
individual patient data, we identified dynamic antimicrobial 
susceptibility profiles among S. Typhi and S. Paratyphi A iso-
lates and a trend of increasing fluoroquinolone MICs corre-
lating with poor outcome. This phenomenon was particularly 
apparent among S. Typhi patients. Although ceftriaxone was 
effective in treating culture-confirmed enteric fever patients, we 
documented poor clinical response in culture-negative patients. 
These data suggest that careful consideration is required for 
antimicrobial therapy of patients with enteric fever. In addition, 
fluoroquinolones should not be recommended for empirical 
treatment of this infection in South Asia [17].
By combining the largest number of enteric fever patients 
from a single location, we were able to identify several notable 
differences in both clinical presentation and clinical response 
between S. Typhi and S. Paratyphi A  patients. Previous work 
conducted at the same center showed the 2 serovars to be clini-
cally indistinguishable [18]. We found that, after controlling for 
age, S. Typhi patients were more likely to report anorexia, diar-
rhea, and coughing and presented with a higher temperature.
Table 4. Fever Clearance Time (in hours) for 4 Enteric Fever Patient Populations by Treatment
Population
Culture Negative Culture Positive Salmonella Typhi Salmonella Paratyphi A
N Median FCT (IQR) Range N Median FCT (IQR) Range N Median FCT (IQR) Range N Median FCT (IQR) Range
Overall 1178 41.3 (18.2–71.3) 1.0–425.5 810 92.7 (65.3–124.7) 1.0–496.0 549 92.0 (66.4–125) 1.0–496.0 261 94.4 (56.1–122.8) 1.0–349.0
Treatment arm
 GAT 585 39.1 (17.0–68.0) 1.0–285.9 416 90.9 (64.3–116.9) 1.0–349.0 283 90.8 (67.4–117.3) 1.0–309.6 133 91.9 (55.8–116.0) 6.8–349.0
 CFX 96 66.5 (18.5–134.5) 4.0–324.0 69 134.0 (82.0–205.0) 16.0–496.0 47 140.0 (96.0–232.0) 40.0–496.0 22 100.0 (81.0–164.0) 16.0–214.0
 CRO 62 102.3 (31.5–161.5) 1.0–354.3 54 73.5 (46.0–112.8) 7.8–232.8 38 82.6 (54.0–117.5) 7.8–215.4 16 53.1 (43.3–83.0) 7.8–232.8
 CHL 239 41.5 (20.2–68.7) 1.0–304.5 169 94.2 (65.2–136.3) 2.8–327.4 120 89.8 (65.2–121.7) 2.8–327.4 49 114.7 (63.4–151.6) 4.4–262.8
 OFX 196 36.8 (17.9–66.4) 1.0–425.5 102 94.8 (56.0–122.3) 1.0–311.8 61 89.8 (48.0–115.4) 3.6–189.8 41 104.4 (71.5–141.6) 1.0–311.8
Abbreviations: CFX, cefixime; CHL, chloramphenicol; CRO, ceftriaxone; FCT, fever clearance time; GAT, gatifloxacin; IQR, interquartile range; OFX, ofloxacin. 
Figure 2. Fever clearance time (FCT) by treatment arm and culture result. FCT (in 
days) is shown for Salmonella Typhi, S. Paratyphi A, and culture-negative patients. 
Colors indicate the different treatment arms. Abbreviations: CFX, cefixime; CHL, 
chloramphenicol; CRO, ceftriaxone; GAT, gatifloxacin; OFX, ofloxacin.
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The precise mechanism driving the variability in MICs over 
time for both S. Typhi and S. Paratyphi A against several anti-
microbials throughout 2005–2014 is unknown but may be 
determined by local prescribing practices. This hypothesis is 
consistent with notable declines in MDR organisms in both 
Nepal and India after fluoroquinolones became the first choice 
of treatment [12, 19, 20]. However, we predict a rapid rebound 
of MDR organisms with reversion to the prescribing of first-
line antimicrobials due to the circulation of MDR plasmids in S. 
Typhi and other organisms [8, 21].
Our study period captured dynamic changes in MICs 
against fluoroquinolones, particularly among S. Typhi iso-
lates in more recent years. Through whole genome sequenc-
ing, we have determined that this rise in MIC is associated 
with the emergence of an H58 variant with mutations in 
the DNA gyrase gene (gyrA) and the DNA topoisomerase 
IV gene (parC) [10, 16]. Supporting these findings, we can 
conclusively show that FCTs and the rate of treatment fail-
ure increases with elevated MICs in S. Typhi patients treated 
with a fluoroquinolone, confirming results from small 
studies conducted elsewhere [7, 22]. However, although S. 
Paratyphi A  isolates had significantly higher MICs against 
all tested fluoroquinolones in comparison to S. Typhi, poor 
outcome was not significantly associated with increasing 
MIC. We suggest continued surveillance of S. Paratyphi A in 
the region to monitor for the emergence of high-level fluo-
roquinolone-resistant organisms similar to trends in the S. 
Typhi population.
As highlighted in our most recent RCT, patients with sus-
pected enteric fever who were blood culture negative were 
treated effectively with gatifloxacin, yet fared less well when 
treated with ceftriaxone [16]. The present analysis shows that 
ofloxacin also performs well in treating those with culture-neg-
ative enteric fever. However, due to the low sensitivity of blood 
culture for the detection of S. Typhi and S. Paratyphi A[23], it 
is likely ofloxacin may have been effective against undetected 
enteric fever cases. We have documented that a reasonable 
proportion (22%, 21/96) of patients enrolled in the third trial 
included in the present analysis [14] who were blood culture 
negative were serologically positive for murine typhus [24]. 
Doxycycline is considered the drug of choice for rickettsial 
infections, although it seems that fluoroquinolones may also 
have clinical activity [24].
In 2003 the World Health Organization published guidelines 
that recommended azithromycin, ceftriaxone, or cefixime for 
quinolone-resistant S. Typhi and S. Paratyphi A infections [23]. 
Figure 3. Distribution of minimum inhibitory concentrations (MICs) against antimicrobials for Salmonella Typhi and S. Paratyphi A. MICs shown on a log2 scale against 
12 antimicrobials for S. Typhi (blue) and S. Paratyphi A (orange). Lower, middle, and upper horizontal dashed lines represent the current Clinical and Laboratory Standards 
Institute cutoffs for susceptible/intermediate and intermediate/resistant, respectively.
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Figure 4. Minimum inhibitory concentrations (MICs) over time for Salmonella Typhi and S. Paratyphi A. MICs shown on a log2 scale for 8 antimicrobials over the period 
2005–2014. Salmonella Typhi are shown in blue and S. Paratyphi A are shown in orange. The smoothed line is derived from the generalized additive model showing a nonlin-
ear increase in MICs over time, with the shaded region showing the 95% confidence interval. Lower, middle, and upper horizontal dashed lines represent the current Clinical 
and Laboratory Standards Institute cutoffs for susceptible/intermediate and intermediate/resistant, respectively.
Figure 5. Fever clearance time and minimum inhibitory concentrations (MICs) against fluoroquinolones for Salmonella Typhi and S. Paratyphi A. Fever clearance time (in 
days) is shown plotted against log2 MIC for gatifloxacin (left) and ofloxacin (right). Salmonella Typhi isolates are shown in blue and S. Paratyphi A isolates are shown in orange. 
The lines represent the best-fit linear model, with 95% confidence interval shown by the shaded region.
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Azithromycin is safe and efficacious for the treatment of uncom-
plicated typhoid [25, 26]. Although there are no current clini-
cal MIC breakpoints, the majority of isolates (88%) here were 
susceptible, using the previously suggested cutoff of <16  µg/
mL [27]. The low MICs against ceftriaxone and rapid FCTs 
throughout the study period indicate that this drug is likely to 
be effective for culture-confirmed enteric fever in Nepal. The 
cost and parenteral route of administration, however, make 
ceftriaxone less suitable for patient treatment in low- and mid-
dle-income countries, particularly as 60%–90% of enteric fever 
patients are treated as outpatients [3]. An alternative would be 
the oral, third-generation cephalosporin cefixime. However, 
our first trial, in which we compared gatifloxacin with cefixime, 
had to be stopped early by the Data Safety Monitoring Board 
because of the high failure rate in the cefixime arm (26/77) 
compared to the gatifloxacin arm (5/92; OR, approximately 9), 
despite all strains being cefixime susceptible [13]. Our analysis 
supports a recommendation for azithromycin or ceftriaxone 
for culture-confirmed enteric fever, and in the absence of rapid 
diagnostics for rickettsial infections [28], a combination of cef-
triaxone and doxycycline in culture-negative febrile patients in 
this setting [16]. However, identification of extended-spectrum 
β-lactamase–producing S. Paratyphi A in India again suggests 
vigilance is required.
Our study has limitations. First, the poor diagnostic sensi-
tivity of blood culture may lead to misclassification of a sig-
nificant number of patients. Although a proportion of culture 
negatives are likely to be positive for Rickettsia spp., this was 
not directly assessed [24]. Furthermore, by combining patients 
from individual RCTs with some differing definitions, the data 
became nonrandomized; however, we included a random effect 
of study to account for heterogeneity between studies and con-
trolled for age. Therefore, strong associations, such as odds 
of treatment failure between cefixime and gatifloxacin in cul-
ture-positive patients, may be reduced with the larger, nonran-
domized data. Additionally, we were unable to access pharmacy 
records to evaluate the relationship of prescribing patterns for 
febrile patients and MICs against common antimicrobials. 
Notwithstanding these limitations, the results from this largest 
collection of trials with patient recruitment spanning a decade 
in an endemic location with a high burden of disease will help 
to inform therapy recommendations.
In conclusion, poor sanitation, low vaccine uptake, and the emer-
gence of extensive ciprofloxacin-resistant S. Typhi in Kathmandu 
suggest that appropriate antimicrobial usage policies are required 
in order to limit morbidity, mortality, and transmission. In this 
large evaluation, we document shifting antimicrobial susceptibility 
profiles, an association between poor treatment outcome, and S. 
Typhi MICs in patients treated with a fluoroquinolone and again 
highlight the need for better diagnostics for febrile diseases in this 
setting. We reiterate that fluoroquinolones should not be recom-
mended for the empirical treatment of enteric fever in South Asia 
[8, 29] and advocate the use of azithromycin or ceftriaxone, in 
addition to surveillance for changes in AMR profiles.
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